Qin C. Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qin C. Ji has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
David B. Duignan
Quantitative, Translational and ADME Sciences, AbbVie Bioresearch Center, Worcester, USA
2 shared publicationsGary J. Jenkins
Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, USA
2 shared publicationsGary Jenkins
AbbVie Inc., DMPK-BA, North Chicago, IL60064, USA
2 shared publicationsJohn P. Savaryn
Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, USA
2 shared publications- Christian Goess
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA
1 shared publication Christopher M. Harris
Discovery Immunology Research, AbbVie Bioresearch Center, Worcester, USA
1 shared publication
Latest Publications
- Open Access
- 4 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 13026
Rapid LC-MS/MS Evaluation of Collagen and Elastin Crosslinks in Human and Mouse Lung Tissue with a Novel Bioanalytical Surrogate Matrix Approach
Alterations to post-translational crosslinking modifications in the extracellular matrix (ECM) are known to drive the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Thus, the methodology for measuring crosslinking dynamics is valuable for understanding disease progression. The existing crosslinking analysis sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are typically labor-intensive and time-consuming which limits throughput. We, therefore, developed a rapid approach minimizing specialized equipment and hands-on time. The LC-MS/MS sample analysis time was reduced to two minutes per sample. We then improved the analytical integrity of the method by developing a novel surrogate matrix approach for the dihydroxylysinonorleucine (DHLNL) crosslink. By modifying sample preparation, we prepared a tissue-based surrogate matrix with undetectable levels of endogenous DHLNL, providing a strategy for quantifying this crosslink with a more relevant standard matrix. We then applied this rapid methodology to evaluating crosslinking in lung fibrosis. We showed an increase in DHLNL in human IPF lung relative to healthy donors, as well as in a fibrotic mouse model. Finally, we demonstrated that this increase in DHLNL could be mitigated with an anti-fibrotic compound, suggesting that this assay has potential for evaluating pharmaceutical compound efficacy.
- 4 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 13026
Open AccessRapid LC-MS/MS Evaluation of Collagen and Elastin Crosslinks in Human and Mouse Lung Tissue with a Novel Bioanalytical Surrogate Matrix Approach
Alterations to post-translational crosslinking modifications in the extracellular matrix (ECM) are known to drive the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Thus, the methodology for measuring crosslinking dynamics is valuable for understanding disease progression. The existing crosslinking analysis sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are typically labor-intensive and time-consuming which limits throughput. We, therefore, developed a rapid approach minimizing specialized equipment and hands-on time. The LC-MS/MS sample analysis time was reduced to two minutes per sample. We then improved the analytical integrity of the method by developing a novel surrogate matrix approach for the dihydroxylysinonorleucine (DHLNL) crosslink. By modifying sample preparation, we prepared a tissue-based surrogate matrix with undetectable levels of endogenous DHLNL, providing a strategy for quantifying this crosslink with a more relevant standard matrix. We then applied this rapid methodology to evaluating crosslinking in lung fibrosis. We showed an increase in DHLNL in human IPF lung relative to healthy donors, as well as in a fibrotic mouse model. Finally, we demonstrated that this increase in DHLNL could be mitigated with an anti-fibrotic compound, suggesting that this assay has potential for evaluating pharmaceutical compound efficacy.
- 1 February 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (3) , 99-101
Introducing the 2023 Bioanalysis Special-Themed Issue on Laboratory Structure and Management for Nonregulated Bioanalysis
- 1 February 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (3) , 99-101
Introducing the 2023 Bioanalysis Special-Themed Issue on Laboratory Structure and Management for Nonregulated Bioanalysis
- 21 February 2022
- Published by Taylor & Francis in Bioanalysis
- Vol. 14 (5) , 279-287
Comparison of Three Parallelism Assessment Methods of Biomarker Quantification by LC-MS/MS: a Case Study of the Bioanalysis of Creatinine in Human Urine Samples
Background: Currently, no regulatory guidelines are available for parallelism assessment for LC-MS biomarker quantification. Spike recovery, standard addition and dilutional linearity are recommend...
- 21 February 2022
- Published by Taylor & Francis in Bioanalysis
- Vol. 14 (5) , 279-287
Comparison of Three Parallelism Assessment Methods of Biomarker Quantification by LC-MS/MS: a Case Study of the Bioanalysis of Creatinine in Human Urine Samples
Background: Currently, no regulatory guidelines are available for parallelism assessment for LC-MS biomarker quantification. Spike recovery, standard addition and dilutional linearity are recommend...
- 1 August 2021
- Published by Elsevier in Journal of Chromatography B
- Vol. 1180, 122897
Fit-for-purpose LC-MS/MS quantification of leukotoxin and leukotoxin diol in mouse plasma without sample pre-concentration
- 1 August 2021
- Published by Elsevier in Journal of Chromatography B
- Vol. 1180, 122897
Fit-for-purpose LC-MS/MS quantification of leukotoxin and leukotoxin diol in mouse plasma without sample pre-concentration